Literature DB >> 30866068

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate® ) and BAY 81-8973 (Kovaltry® ) in patients with severe or moderate haemophilia A in prophylaxis.

Juan Eduardo Megías-Vericat1,2, Santiago Bonanad2, Saturnino Haya2, Ana Rosa Cid2, María Remedios Marqués1, Emilio Monte-Boquet1, Sofía Pérez-Alenda2,3, Pau Bosch2, Felipe Querol2,3, José Luis Poveda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30866068     DOI： 10.1111/hae.13733

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  4 in total

1.  Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection.

Authors:  Alexander Solms; Shadan Lalezari; Anita Shah; Gili Kenet
Journal:  Haemophilia       Date:  2020-04-16       Impact factor: 4.287

2.  BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.

Authors:  Cristina Santoro; Beng Fuh; Phu Quoc Le; Philip Maes; Rubén Berrueco; Eva Maria Mingot-Castellano; Sylvia von Mackensen; Alexander Solms; Michael Wang
Journal:  Eur J Haematol       Date:  2020-04-23       Impact factor: 2.997

3.  Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates.

Authors:  Kun Huang; Yingzi Zhen; Gang Li; Xinyi Wu; Zhenping Chen; Runhui Wu
Journal:  Res Pract Thromb Haemost       Date:  2022-03-25

4.  Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.

Authors:  Rong Chen; Dmitry Gultyaev; Johanna Lister; Rong Han; Nan Hu; Jean Malacan; Alexander Solms; Parth Vashi; Jamie O'Hara; Shanlian Hu
Journal:  BMC Med Res Methodol       Date:  2022-08-05       Impact factor: 4.612
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.